AstraZeneca spends a few million dollars a year on its Emerging Innovations Unit, with other research funding coming from outside sources. "AstraZeneca Gives Rejected Drugs a Second Life," at 1100 GMT, incorrectly stated that the company spent tens of millions of dollars a year on the unit in the 14th paragraph. Also, AstraZeneca shelved a schizophrenia drug candidate because it didn't work in schizophrenia. An earlier version of this article incorrectly stated it was shelved because of its hormonal side effects in the 17th paragraph.

(END) Dow Jones Newswires

March 13, 2017 10:51 ET (14:51 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more AstraZeneca Charts.